Metsera, Inc.
MTSR
Rangering i aksjer
#2568
Metsera, Inc. operates as a clinical-stage biotechnology firm, specializing in... Metsera, Inc. operates as a clinical-stage biotechnology firm, specializing in crafting both injectable and oral nutrient-stimulated hormone analog peptides. These therapeutic compounds are primarily aimed at addressing obesity, overweight conditions, and associated health issues. Its developmental pipeline features MET-097i and MET-233i, both under investigation for treating obesity and overweight patients. Furthermore, Metsera is advancing a potential combination therapy involving MET-233i and MET-097i. The company is also progressing additional drug candidates, including MET-002, MET-224o, MET-067i, and MET-034i, all of which target disorders such as diabetes and obesity. Founded in 2022, Metsera, Inc. maintains its corporate headquarters in New York, New York.
Aksjekurs
$70.50
Sist synkronisert: 2025-11-14
Markedsverdi
$7.33B
Endring (1 dag)
0.00%
Endring (1 år)
33.60%
Land
US
Handel Metsera, Inc. (MTSR)
Kategori
Healthcare
Aksjeprishistorikk for Metsera, Inc. (MTSR)
Høyeste sluttskurs: $72.34 den 2025-11-01
Laveste sluttskurs: $26.50 den 2025-01-01
Laveste sluttskurs: $26.50 den 2025-01-01
Aksjeprishistorikk for Metsera, Inc. fra 2025 til 2026
Årlig aksjeprisytelse
| År | Ytelse |
|---|---|
| 2026 (TTM) | -10.54% |
| 2025 | 0.00% |
Aksjepris for lignende selskaper eller konkurrenter
| Selskap | Aksjepris | Endring 1år% | Land |
|---|---|---|---|
| $530.66 | 24.44% |
US
|
|
| $230.18 | 757.28% |
US
|
|
| $137.83 | -3.78% |
AU
|
|
| $890.66 | 9.40% |
NL
|
|
| $290.41 | 2.03% |
BE
|
